The Evaluation of Treatment Sequencing in Plant-Resistant Ovarian Cancer

Rob Coleman, Chief Medical Officer for Surakan Research Institute. What were some of the key findings previously seen in the Sareya trial? We had shown last year that the objective response rate was over 32%, and with a duration of response, almost seven months. This year, we presented analyses on updating the efficacy in those subgroups That I mentioned. The patients who had received Mervituxumab as their first regimen but then also to look at the efficacy with respect to duration of response if they had seen this in later lines of treatment exposure.